Financing rounds since 2013 have grown larger in San Diego life sciences. A look at annual median deal size shows an increase, from early-stage seed financing to Series A, C and D rounds. Only Series B rounds have remained flat in recent years.
Aristea Therapeutics emerged Dec. 18 with a $15 million series A round and mission revolving around inflammatory diseases.
Shares of Evofem rose on Dec. 17 after the company reported that its birth control gel worked as intended in late-stage clinical trials.
Serial biotech entrepreneur Jonathan Lim is back at it.
Aethlon Medical, a San Diego company, named Timothy Rodell as interim CEO, it was announced Dec. 13.
Technology, Talent Keep Area’s Agriculture Growing Strong
Decades ago on North County farms, the Ecke family turned the poinsettia into a top-selling Christmas plant. From former Ecke land, Cibus again wants to put the region on the map.
A medical tourism campaign touting San Diego’s hospitals, genomics companies and sunny weather is trying to find its groove.
Adamis Pharmaceuticals’ epipen alternative will launch nationally in the first quarter of next year, the company said in a recent update.
San Diego-based Neurocrine’s drug for Tourette syndrome failed to meet its primary goal in a mid-stage clinical trial, the company reported Dec. 12.
The San Diego Business Journal frequently chronicles local funding rounds and the big dreams that accompany them. But what about the largest venture capital sources locally?